𝐅𝐃𝐀 𝐀𝐩𝐩𝐫𝐨𝐯𝐞𝐬 𝐍𝐞𝐮𝐫𝐨𝐭𝐞𝐜𝐡’𝐬 𝐄𝐍𝐂𝐄𝐋𝐓𝐎 𝐂𝐞𝐥𝐥 𝐓𝐡𝐞𝐫𝐚𝐩𝐲 𝐟𝐨𝐫...
𝐀𝐝𝐯𝐞𝐫𝐮𝐦’𝐬 𝐆𝐞𝐧𝐞 𝐓𝐡𝐞𝐫𝐚𝐩𝐲 𝐟𝐨𝐫 𝐖𝐞𝐭 𝐀𝐌𝐃 𝐄𝐚𝐫𝐧𝐬 𝐅𝐃𝐀’𝐬 𝐑𝐌𝐀𝐓 𝐃𝐞𝐬𝐢𝐠𝐧𝐚𝐭𝐢𝐨𝐧.
👏 Adverum Biotechnologies has received the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation for its gene therapy, lxoberogene soroparvovec (Ixo-vec), aimed at treating wet age-related macular degeneration (AMD). This designation is based on promising early clinical data and could expedite the therapy’s development. Ixo-vec, which uses Adverum’s proprietary AAV.7m8 vector technology, has already shown potential in reducing treatment burden and maintaining vision. The company plans to continue its collaboration with regulators, with updates expected later this year.
